Tacrolimus eye drops can be used to treat refractory vernal keratoconjunctivitis

Article

Topical 0.0005% tacrolimus eye drops are a safe and effective treatment for refractory vernal keratoconjunctivitis (VKC).

Topical 0.0005% tacrolimus eye drops are a safe and effective treatment for refractory vernal keratoconjunctivitis (VKC), according to data published in Eye.

Dr A. Kheirkhah et al., Farabi Eye Hospital, Eye Research Center, Tehran University of Medical Sciences, Iran, conducted the prospective study on 20 eyes of 10 patients with refractory VKC. Patients stopped using other medications and were treated with 0.0005% tacrolimus eye drops four times daily. The outcome measures included changes in subjective symptoms, objectives symptoms post-treatment and the progression of potential complications.

Patients presented with symptoms including itching, redness, photosensitivity, foreign body sensation and mucus discharge. After treatment all symptoms demonstrated signs of improvement. Objective signs such as conjunctival hyperaemia, conjunctival papillary hypertrophy, giant papillae, limbal hypertrophy, corneal punctate epithelial erosions, and corneal pannus also showed improvement.

There were no ocular complications associated with tacrolimus and additional treatment for further relief was not necessary. The study suggests the long-term use of tacrolimus for the most effective results.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.